|
| |
Capsulution Nanoscience AG -
Further Fundamental Patent Grant is Imminent
Berlin, Germany
(November 28, 2005) - Following a recent notice from the European Patent
Office, Berlin-based Capsulution Nanoscience AG can announce that a further
fundamental patent grant for its innovative nano- and microencapsulation
technology - known as the LBL-Technology® - is imminent.
The patent with the number EP 1064087 covers the manufacture of multifunctional
nano- and micron-sized capsules. The tiny capsules can be filled with
pharmaceutical drug compounds as well as with other active substances. On the
basis of the LBL-Technology® Capsulution develops advanced drug delivery
systems, which bring drugs more safely and effectively to the right site of the
body.
"This patent grant will secure the sustainability and the defence of our
competitive advantage in the field as one of the leading developers of nano- and
microcapsules intended for life science applications," said Dr. Andreas Voigt,
Chief Scientific Officer of Capsulution Nanoscience. "Finally, we can support
our industrial clients, who demand for highly differentiated products in the
market, which can be sustained over a long period of time.²
The LBL-Technology® represents a versatile encapsulation system. For the actual
encapsulation, a wide range of FDA-approved polymers can be used. In addition,
the capsules' surface can be functionalized to suit a targeted release in the
human body.
Broad field of applications:
Capsulution's LBL-Technology® platform will soon be used for a wide range of
applications. LBL-Solv® is a means of drug reformulation, where water insoluble
active compounds are nanoencapsulated to increase their bioavailability. In
addition, LBL-Intra is an application specific to intracellular drug delivery.
The capsules may also be applied to improve the function of drug-releasing
implants as well as to aid the development of nanodiagnostics.
About Capsulution NanoScience AG:
Capsulution NanoScience AG develops innovative nano- and micron-sized capsules.
The company applies its worldwide-patented so-called LBL-Technology®. Based on
their minute size, their functionality and their highly reproducible production
process the capsules can be used for a multitude of different applications.
Accordingly, the precisely sized capsules (500 nm to 50 µm) can be made to
function in a manner to suit the intended application, and can be given the
appropriate biochemical, electrical, optical and magnetic properties as required
by the customer. In order to meet customers' needs for complete product
solutions Capsulution has recently designated a Japanese licensee as the
preferred developer, manufacturer and distributor for automated LBL-units. The
contract, which included significant upfront payments as well as royalties for
Capsulution, assures the easy adaptation of the LBL-capsule manufacturing
process by Capsulution's industrial clients. Only six month after the signing of
the licence agreement, EBARA has started operation of the first prototype plant
(LBL-Unit®) for the manufacture of Capsulution's LBL capsules. The mobile unit
will already be applied for first feasibility studies on behalf of several
renowned Japanese industrial clients, who are active in the pharmaceutical,
cosmetic and food sectors. By applying Capsulution's proprietary nano-encapsulation
technology clients expect significantly enhanced product properties, like the
improvement of the bioavailability of novel cancer and asthma drugs in the human
body as well as convenience and compliance. The pilot plant that took up
operation at the beginning of October 2005 in Tokyo will initially produce
between one and five kilograms of encapsulated active compounds per day. Today,
the Berlin-based company has 16 highly qualified employees. Amongst
Capsulution's clients and partners are key industry players.
Downloads: see "Presse Pool" of
www.biocommunications.net
Further Information:
Capsulution NanoScience AG
Alexander Herrmann (CFO)
Volmerstr. 7b
D - 12489 Berlin
Tel.: +49-30-6392-3627
Fax: +49-30-6392-3601
Web: www.capsulution.com
eMail: alexander.herrmann@capsulution.com
| |
|
